natgillin/translations-raw huggingface dataset:
• Turn the mixing bottle upside-down together with the syringe. 
• Okrenite bočicu za miješanje naopako zajedno sa štrcaljkom.
Patients should be clinically evaluated periodically and continuation of treatment should be decided on an individual basis by the treating physician. 
Bolesnici bi trebali periodički biti klinički evaluirani i nadležni liječnik bi trebao, ovisno o nalazima, donijeti odluku o nastavku liječenja za svakog bolesnika ponaosob.
Eltrombopag was studied in a single-arm, single-centre open-label study in 43 patients with severe aplastic anaemia with refractory thrombocytopenia following at least one prior immunosuppressive therapy (IST) and who had a platelet count ≤30,000/µl. 
Eltrombopag se proučavao u otvorenom ispitivanju s jednom skupinom koje se provodilo u jednom centru, u 43 bolesnika s teškom aplastičnom anemijom s refrakternom trombocitopenijom nakon najmanje jedne prethodne imunosupresivne terapije (IST), koji su imali broj trombocita ≤30 000/μl.
Bone marrow reticulin formation and risk of bone marrow fibrosis 
Retikulinska formacija koštane srži i rizik od fibroze koštane srži
The sudden blocking of a blood vessel by a blood clot is an uncommon side effect and may affect up to 1 in 100 people. 
Iznenadno začepljenje krvne žile krvnim ugruškom je manje česta nuspojava koja se može javiti u do 1 na 100 osoba.
The objective of treatment with eltrombopag should not be to normalise platelet counts. 
Cilj liječenja eltrombopagom ne bi trebao biti normalizacija broja trombocita.
Treatment with eltrombopag should be reinitiated in accordance with dosing and administration recommendations (see section 4.2). 
Potrebno je ponovno započeti liječenje eltrombopagom u skladu s preporukama o doziranju i načinu primjene (vidjeti dio 4.2).
Carcinogenicity and mutagenicity 
Karcinogenost i mutagenost
Plasma eltrombopag Cmax and AUC(0-) estimates for patients with HCV enrolled in the phase III studies are presented for each dose studied in Table 9. 
Procjene Cmax i AUC(0-) eltrombopaga u plazmi za bolesnike s HCV-om uključene u fazu III ispitivanja za svaku ispitivanu dozu prikazane su u tablici 9.
• decreased levels of white blood cells 
• smanjena razina bijelih krvnih stanica
At baseline, more than 70% of ITP patients in each treatment group reported any bleeding (WHO Grades 1-4) and more than 20% reported clinically significant bleeding (WHO Grades 2-4), respectively. 
Na početku ispitivanja više od 70% bolesnika s ITP-om u svakoj ispitivanoj skupini prijavilo je bilo koji oblik krvarenja (WHO stupanj 1-4), a više od 20% je prijavilo klinički značajno krvarenje (WHO stupanj 2-4).
Stop eltrombopag; increase the frequency of platelet monitoring to twice weekly. 
Prekinuti primjenu eltrombopaga, povećati učestalost praćenja trombocita na dva puta tjedno.
Revolade can make you dizzy and have other side effects that make you less alert. 
Od lijeka Revolade možete osjećati omaglicu te imati druge nuspojave koje Vam mogu smanjiti pozornost.
The effectiveness and safety of Revolade have not been established for the treatment of thrombocytopenia due to MDS. 
Učinkovitost i sigurnost Revoladea nisu utvrđene za liječenje trombocitopenije koja je posljedica MDS-a.
In both RAISE and TRA100773B the response to eltrombopag relative to placebo was similar irrespective of ITP medicinal product use, splenectomy status and baseline platelet count (≤15,000/µl, >15,000/µl) at randomisation. 
U oba ispitivanja - RAISE i TRA100773B, odgovor na eltrombopag u odnosu na placebo je bio sličan, bez obzira na primjenu drugih lijekova za liječenje ITP-a, splenektomiranost bolesnika ili početni broj trombocita (≤15 000/µl, >15 000/µl) na početku randomizacije.
If the patient develops new or worsening morphological abnormalities or cytopenia(s), treatment with eltrombopag should be discontinued and a bone marrow biopsy considered, including staining for fibrosis. 
Ukoliko bolesnik razvije pogoršanje ili nove morfološke abnormalnosti ili citopeniju, liječenje eltrombopagom treba prekinuti i razmotriti biopsiju koštane srži, uključujući bojanje kojim se otkriva fibroza.
The safety of eltrombopag in severe aplastic anaemia was assessed in a single-arm, open-label study (N=43) in which 11 patients (26%) were treated for >6 months and 7 patients (21%) were treated for >1 year. 
Sigurnost eltrombopaga kod teške aplastične anemije ocijenjena je u otvorenom ispitivanju s jednom skupinom (N=43) u kojem se 11 bolesnika (26%) liječilo >6 mjeseci, a 7 bolesnika (21%) liječilo se >1 godine.
In a small number of ITP patients, eltrombopag treatment was discontinued due to bone marrow reticulin (see section 4.4). 
Kod malog broja bolesnika s ITP-om liječenje eltrombopagom je prekinuto zbog umnožavanja retikulina u koštanoj srži (vidjeti dio 4.4).
• skin discolouration 
• diskoloracija kože
Plasma eltrombopag AUC(0-) and Cmax estimates for ITP patients are presented (Table 8). 
Prikazani su AUC(0-) eltrombopaga u plazmi i procjene Cmax za bolesnike s ITP-om (tablica 8).
• sleep disorders, abnormal drowsiness, depression, anxiety 
• poremećaji spavanja, neuobičajena omamljenost, depresija, tjeskoba
Forty-two to 60% of the eltrombopag-treated patients in the RAISE study were receiving 75 mg from Day 29 to the end of treatment. 
Četrdeset dva do 60% bolesnika liječenih eltrombopagom u RAISE studiji primalo je dozu lijeka od 75 mg, od 29. dana do kraja ispitivanog perioda liječenja.
Very common side effects that may show up in the blood tests • abnormal changes to the cells in your bone marrow 
Vrlo česte nuspojave koje se mogu vidjeti u krvnim pretragama • abnormalne promjene stanica u Vašoj koštanoj srži
Safety and efficacy have not been established in combination with direct-acting antiviral agents approved for treatment of chronic hepatitis C infection. 
Sigurnost i djelotvornost primjene eltrombopaga nisu utvrđene za primjenu lijeka u kombinaciji s izravno djelujućim antivirusnim lijekovima koji su odobreni za liječenje kronične infekcije hepatitisom C.
Caution should be exercised in these patients (see section 4.4). 
Potreban je oprez pri primjeni lijeka kod tih bolesnika (vidjeti dio 4.4).
How to take Revolade 
Kako uzimati Revolade
• swelling in the hands or feet 
• trnci ili utrnulost u rukama ili nogama
In vitro studies suggest that CYP1A2 and CYP2C8 are responsible for oxidative metabolism of eltrombopag. 
In vitro ispitivanja upućuju na to da su CYP1A2 i CYP2C8 odgovorni za oksidativni metabolizam eltrombopaga.
Make sure the plunger is pushed all the way into the syringe. 
Provjerite da je klip gurnut u štrcaljku do kraja.
The TPO-R is predominantly expressed on the surface of cells of the myeloid lineage. 
TPO-R su prvenstveno prisutni na površini stanica mijeloidne loze.
These tests will be repeated at intervals while you are taking it. 
Ove će se pretrage ponavljati redovito tijekom uzimanja ovog lijeka.
These may affect up to 1 in 10 people. 
Mogu se javiti u do 1 na 10 osoba.
If the abnormalities are confirmed, serum liver tests should be monitored until the abnormalities resolve, stabilise, or return to baseline levels. 
Ako se abnormalne vrijednosti jetrenih enzima potvrde ponovnim testiranjem, jetrene enzime treba pratiti do nestanka tih abnormalnih vrijednosti, stabilizacije ili vraćanja na početne vrijednosti.
• irritability, generally feeling unwell, chest pain and discomfort 
• razdražljivost, općenito loše osjećanje, bol u prsnom košu i nelagoda
For SAA patients refractory to or heavily pretreated with prior immunosuppressive therapy, bone marrow examination with aspirations for cytogenetics is recommended prior to initiation of eltrombopag, at 3 months of treatment and 6 months thereafter. 
Za bolesnike s teškom aplastičnom anemijom koji su refrakterni na prethodnu imunosupresivnu terapiju ili jako pretretirani istom, preporučuje se pregled koštane srži s aspiracijama za citogenetiku prije započinjanja primjene eltrombopaga, nakon 3 mjeseca liječenja te nakon 6 mjeseci.
Common Blood creatine phosphokinase increased 
Pretrage često povišena kreatin fosfokinaza u krvi
Do not use this medicine after the expiry date which is stated on the carton and the blister. 
Ovaj lijek se ne smije upotrijebiti nakon isteka roka valjanosti navedenog na kutiji i blisteru.
The plasma eltrombopag concentration-time data collected in 88 patients with ITP in studies TRA100773A and TRA100773B were combined with data from 111 healthy adult subjects in a population PK analysis. 
Podaci o koncentraciji eltrombopaga u plazmi kroz vrijeme, prikupljeni u 88 bolesnika s ITP-om u ispitivanjima TRA100773A i TRA100773B, udruženi su s podacima 111 zdravih odraslih ispitanika u analizi farmakokinetike u populaciji.
However, cataracts were not observed in juvenile rats given tolerated doses at 5 times the human clinical exposure in paediatric ITP patients, based on AUC. 
Međutim, katarakte nisu bile uočene u juvenilnih štakora kojima su davane podnošljive doze koje su 5 puta veće od kliničke izloženosti u pedijatrijskih bolesnika s ITPom, mjerene AUC-om.
PARTICULARS TO APPEAR ON INTERMEDIATE CARTON 
PODACI KOJI SE MORAJU NALAZITI NA SREDNJOJ KUTIJI
The haematological response rate was 40% (17/43 patients; 95 % CI 25, 56), the majority were unilineage responses (13/17, 76%) whilst there were 3 bilineage and 1 trilineage responses at week 12. 
Stopa hematološkog odgovora bila je 40% (17/43 bolesnika; 95% CI 25, 56), pri čemu je većina bila s odgovorom u jednoj lozi (13/17, 76%) te su bila 3 odgovora u dvije loze i 1 odgovor u tri loze u 12. tjednu.
Over 50% of responders who were transfusion-dependent at baseline, had >80% reduction in both platelet and RBC transfusion requirements compared to baseline. 
Više od 50% bolesnika s odgovorom koji su bili na početku ovisni o transfuziji imalo je smanjenje od >80% u potrebama za transfuzijom i trombocita i eritrocita u usporedbi s početnim stanjem.
ENABLE 1 (TPL103922 n=716) and ENABLE 2 (TPL108390 n=805) were randomised, double-blind, placebo-controlled, multicentre studies to assess the efficacy and safety of Revolade in thrombocytopenic patients with HCV infection who were otherwise eligible to initiate antiviral therapy. 
ENABLE 1 (TPL103922 n=716) i ENABLE 2 (TPL108390 n=805) su bila randomizirana, dvostruko slijepa, placebom kontrolirana ispitivanja u više centara za procjenu učinkovitosti i sigurnosti Revoladea u bolesnika s trombocitopenijom i HCV infekcijom koji su inače imali pravo započeti antiviralnu terapiju.
Revolade 75 mg film-coated tablets also contain iron oxide red (E172) and iron oxide black (E172). 
Revolade 75 mg filmom obložene tablete također sadrže i željezov oksid crveni (E172) i željezov oksid crni (E172).
They are supplied in aluminum blisters in a carton containing 14 or 28 film-coated tablets and multipacks containg 84 (3 packs of 28) film-coated tablets). 
Dostupne su u aluminijskim blisterima u kutiji koja sadrži 14 ili 28 filmom obloženih tableta i u višestrukom pakiranju koje sadrži 84 (3 pakiranja po 28) filmom obloženih tableta.
• Give the entire contents of the bottle to the patient using one of the accompanying oral syringes. 
• Dajte cijeli sadržaj boce bolesniku pomoću jedne od priloženih štrcaljki za usta.
The dose of eltrombopag should be adjusted in 50 mg increments every 2 weeks as necessary to achieve the target platelet count ≥50,000/µl. 
Dozu eltrombopaga potrebno je prilagoditi povećavajući je prema potrebi za po 50 mg svaka 2 tjedna kako bi se postigla ciljana vrijednost broja trombocita ≥50 000/µl.
In vitro studies demonstrated that eltrombopag is not a substrate for the organic anion transporter polypeptide, OATP1B1, but is an inhibitor of this transporter (IC50 value of 2.7 μM (1.2 μg/ml). 
In vitro ispitivanja pokazala su da eltrombopag nije supstrat za polipeptidni transporter organskih aniona OATP1B1, nego je njegov inhibitor (IC50 vrijednost od 2,7 μM (1,2 μg/ml).
Eligible for efficacy analysis, n Patients with platelet count 50,000/l after up to 42 days of dosing (compared to a baseline count of <30,000/l), n (%) 
Pogodni za analizu djelotvornosti, n Bolesnici s brojem trombocita 50 000/l, do 42. dana liječenja (u usporedbi s početnim brojem <30 000/l), n (%)
• fever, headache 
• vrućica, glavobolja
In clinical studies, platelet counts generally began to increase within 1 week of starting eltrombopag. 
U kliničkim ispitivanjima broj trombocita se obično počeo povisivati unutar 1 tjedna nakon započinjanja liječenja eltrombopagom.
Summary of the safety profile Immune thrombocytopenia in adult and paediatric patients 
Sažetak sigurnosnog profila Imunosna trombocitopenija u odraslih i pedijatrijskih bolesnika
Administration of a single dose of eltrombopag 75 mg with a polyvalent cation-containing antacid (1524 mg aluminium hydroxide and 1425 mg magnesium carbonate) decreased plasma eltrombopag AUC0- by 70% (90% CI: 64%, 76%) and Cmax by 70% (90% CI: 62%, 76%). 
Primjena jedne doze eltrombopaga od 75 mg s antacidom koji sadrži polivalentne katione (1524 mg aluminijeva hidroksida i 1425 mg magnezijeva karbonata) smanjila je plazmatski AUC0- eltrombopaga za 70% (90% CI: 64%, 76%) i Cmax za 70% (90% CI: 62%, 76%).
EXP Use within 30 minutes of reconstitution. 
Rok valjanosti Primijeniti unutar 30 minuta od pripreme.
Administration of eltrombopag 75 mg once daily for 5 days with a single 10 mg dose of the OATP1B1 and BCRP substrate rosuvastatin to 39 healthy adult subjects increased plasma rosuvastatin Cmax 103% (90% confidence interval [CI]: 82%, 126%) and AUC0- 55% (90% CI: 42%, 69%). 
Primjena 75 mg eltrombopaga jednom dnevno kroz 5 dana, uz jednokratnu dozu od 10 mg OATP1B1 i BCRP supstrata rosuvastatina u 39 zdravih odraslih ispitanika, povisila je plazmatski Cmax rosuvastatina za 103% (90%-ni interval pouzdanosti [CI]: 82%, 126%) i AUC0- za 55% (90% CI: 42%, 69%).
Reported adverse reactions included mild rash, transient bradycardia, ALT and AST elevation, and fatigue. 
Prijavljene nuspojave uključivale su blagi osip, prolaznu bradikardiju, porast ALT i AST i umor.
The improvement in the proportion of patients who achieved SVR was consistent across all subgroups in the randomisation strata (baseline platelet counts (<50,000 vs. >50,000), viral load (<800,000 IU/ml vs. ≥800,000 IU/ml) and genotype (2/3 vs. 1/4/6)). 
Poboljšanje u udjelu bolesnika koji su postigli SVR bilo je konzistentno kroz sve podskupine u randomizacijskom stratumu (početni broj trombocita (<50 000 nasuprot >50 000), količina virusa (<800 000 IU/ml nasuprot 800 000 IU/ml) i genotip (2/3 nasuprot 1/4/6)).
Platelet counts should be closely monitored and consideration given to reducing the dose or discontinuing eltrombopag treatment if the platelet count exceeds the target levels (see section 4.2). 
Broj trombocita treba pažljivo pratiti i razmisliti o smanjenju doze ili prekidu liječenja eltrombopagom ako broj trombocita prijeđe ciljne vrijednosti (vidjeti dio 4.2).
Results of a drug-drug pharmacokinetic (PK) interaction study show that co-administration of repeat doses of boceprevir 800 mg every 8 hours or telaprevir 750 mg every 8 hours with a single dose of eltrombopag 200 mg did not alter plasma eltrombopag exposure to a clinically significant extent. 
Rezultati ispitivanja farmakokinetičkih interakcija lijek-lijek pokazuju da istodobna primjena ponovljenih doza boceprevira od 800 mg svakih 8 sati ili telaprevira od 750 mg svakih 8 sati s jednom dozom eltrombopaga od 200 mg nije promijenila u klinički značajnoj mjeri koncentraciju eltrombopaga u plazmi.
TRA100773B: The primary efficacy endpoint was the proportion of responders, defined as ITP patients who had an increase in platelet counts to 50,000/l at Day 43 from a baseline of <30,000/l; patients who withdrew prematurely due to a platelet count 200,000/l were considered responders, those that discontinued for any other reason were considered non-responders irrespective of platelet count. 
TRA100773B: Primarna mjera ishoda djelotvornosti bila je udio bolesnika koji su odgovorili na liječenje (tzv. „respondera“), osoba s ITP-om u kojih je do 43. dana ispitivanja s početne vrijednosti od <30 000/l, došlo do porasta broja trombocita na 50 000/l; bolesnici koji su prijevremeno prekinuli ispitivanje zbog porasta broja trombocita 200 000/l su također smatrani „responderima“, a oni koji su prekinuli sudjelovanje u ispitivanju iz bilo kojeg drugog razloga smatrani su „non-responderima“, bez obzira na broj trombocita.
If new cytogenetic abnormalities are detected, it must be evaluated whether continuation of eltrombopag is appropriate. 
Ako se uoče nove citogenetske abnormalnosti, mora se ocijeniti je li nastavak liječenja eltrombopagom primjeren.
Ocular changes 
Promjene na očima
EU/1/10/612/013 (30 sachets of powder for oral suspension) 
EU/1/10/612/013 (30 vrećica praška za oralnu suspenziju)
Revolade 50 mg film-coated tablets also contain iron oxide red (E172) and iron oxide yellow (E172). 
Revolade 50 mg filmom obložene tablete također sadrže i željezov oksid crveni (E172) i željezov oksid žuti (E172).
Preliminary results from a supportive study (Study ELT116826), an ongoing non-randomised, phase II, single-arm, open-label study in refractory SAA patients, showed consistent results. 
Preliminarni rezultati iz potpornog ne-randomiziranog otvorenog ispitivanja faze II s jednom skupinom (ispitivanje ELT116826) u refrakternih bolesnika s teškom aplastičnom anemijom koje je trenutno u tijeku, pokazali su konzistentne rezultate.
You will be monitored for any signs or symptoms of side effects and given appropriate treatment immediately. 
Pratit će se pojava eventualnih znakova ili simptoma nuspojava te ćete u slučaju njihove pojave odmah dobiti odgovarajuće liječenje.
In eltrombopag clinical studies in ITP thromboembolic events were observed at low and normal platelet counts. 
U kliničkim ispitivanjima eltrombopaga u bolesnika s ITP-om, tromboembolijski događaji (TED) su primijećeni i pri niskom i normalnom broju trombocita.
Thrombocytopenia with HCV infection in adult patients 
Trombocitopenija s HCV infekcijom u odraslih bolesnika
Eltrombopag dose adjustment is permitted during the course of the treatment based on the patient's platelet count (see section 4.2). 
Prilagođavanje doze eltrombopaga dopušteno je tijekom liječenja temeljem broja trombocita svakog pojedinog bolesnika (vidjeti dio 4.2).
Thrombotic/thromboembolic events (TEEs) 
Trombotični/tromboembolijski događaji (TED)
Patients with impaired renal function should use eltrombopag with caution and close monitoring, for example by testing serum creatinine and/or performing urine analysis (see section 5.2). 
Bolesnici s oštećenom bubrežnom funkcijom moraju uzimati eltrombopag s oprezom i biti detaljno praćeni, npr. kontrolom serumskog kreatinina i/ili analizom urina (vidjeti dio 5.2).
ITP study population 
Ispitivana populacija s ITP-om
Revolade is indicated in adult patients with acquired severe aplastic anaemia (SAA) who were either refractory to prior immunosuppressive therapy or heavily pretreated and are unsuitable for haematopoietic stem cell transplantation (see section 5.1). 
Revolade je indiciran u odraslih bolesnika sa stečenom teškom aplastičnom anemijom koji su ili refrakterni na prethodnu imunosupresivnu terapiju ili jako pretretirani i neprikladni za transplantaciju hematopoetskih matičnih stanica (vidjeti dio 5.1).
Serum discolouration and interference with total bilirubin and creatinine testing have been reported in patients taking Revolade. 
U bolesnika koji uzimaju Revolade zabilježeni su diskoloracija seruma i interferencija s testovima za ukupni bilirubin i kreatinin.
• yellowing of the skin or the whites of the eyes (jaundice) 
• žutilo kože ili bjeloočnica (žutica)
Revolade is indicated in adult patients with chronic hepatitis C virus (HCV) infection for the treatment of thrombocytopenia, where the degree of thrombocytopenia is the main factor preventing the initiation or limiting the ability to maintain optimal interferon-based therapy (see sections 4.4 and 5.1). 
Revolade je indiciran za liječenje trombocitopenije u odraslih bolesnika s kroničnom infekcijom virusom hepatitisa C (HCV) u kojih je stupanj trombocitopenije glavni čimbenik koji sprječava započinjanje ili ograničava mogućnost održavanja optimalnog liječenja interferonom (vidjeti dijelove 4.4 i 5.1).
Phototoxicity 
Fototoksičnost
When eltrombopag is given in combination with antivirals reference should be made to the full summary of product characteristics of the respective coadministered medicinal products for comprehensive details of relevant safety information or contraindications. 
Pri primjeni eltrombopaga u kombinaciji s antiviroticima, za detalje o važnim sigurnosnim informacijama ili kontraindikacijama potrebno je vidjeti cjelovite Sažetke opisa svojstava pojedinih lijekova koji se istodobno primjenjuju.
Therefore, caution should be used when co-administration of eltrombopag with lopinavir/ritonavir takes place. 
Stoga je potreban oprez prilikom istodobne primjene eltrombopaga i lopinavira/ritonavira.
g.h/ml a, g/ml Cmax 
N AUC(0-) a, g.h/ml a, g/ml Cmax
Empty the water into the mixing bottle. 
12. Ispraznite vodu u bočicu za miješanje.
Paediatric population aged 1 to 5 years The recommended starting dose of eltrombopag is 25 mg once daily. 
Pedijatrijska populacija u dobi od 1 do 5 godina Preporučena početna doza eltrombopaga je 25 mg jednom dnevno.
In both studies, patients with a platelet count of <75,000/µl were enrolled and stratified by platelet count (<50,000/µl and ≥50,000/µl to <75,000/µl), screening HCV RNA (<800,000 IU/ml and ≥800,000 IU/ml), and HCV genotype (genotype 2/3, and genotype 1/4/6). 
U oba ispitivanja su bolesnici s brojem trombocita <75 000/µl uključeni i stratificirani prema broju trombocita (<50 000/µl i ≥50 000/µl do <75 000/µl), HCV RNA pri probiru (<800 000 IU/ml i ≥800 000 IU/ml) te HCV genotipu (genotip 2/3, i genotip 1/4/6).
Platelet counts should be monitored weekly during antiviral therapy until a stable platelet count is achieved, normally around 50,000-75,000/µl. 
Broj trombocita tijekom antivirusnog liječenja potrebno je pratiti svakoga tjedna, sve do postizanja stabilnog broja trombocita, obično oko 50 000-75 000/µl.
The influence of gender on the pharmacokinetics of eltrombopag was evaluated using a population pharmacokinetic analysis in 111 healthy adults (14 females) and 88 patients with ITP (57 females). 
Utjecaj spola na farmakokinetiku eltrombopaga procjenjivan je koristeći podatke iz populacijske analize farmakokinetike 111 zdravih odraslih osoba (14 žena) i 88 bolesnika s ITP-om (57 žena).
The adverse reactions in the adult ITP studies (N=763), paediatric ITP studies (N=171), the HCV studies (N=1,520), the SAA studies (N=43) and post-marketing reports are listed below by MedDRA system organ class and by frequency. 
Nuspojave iz ispitivanja odraslih s ITP-om (N=763), pedijatrijskih ispitanika s ITP-om (N=171), ispitivanja HCV-a (N=1520), ispitivanja teške aplastične anemije (N=43) te izvješća nakon stavljanja lijeka u promet navedene su niže prema MedDRA klasifikaciji organskih sustava i učestalosti.
rash, itching, skin lesion 
(petehije), osip, svrbež, kožne lezije
Patients were randomised 2:1 and received Revolade (n=63) or placebo (n=29) for up to 13 weeks in the randomised period of the study. 
Bolesnici su bili randomizirani u omjeru 2:1 i primali su Revolade (n=63) ili placebo (n=29) do 13 tjedana u randomiziranom razdoblju ispitivanja.
Following administration of a single 50 mg dose, the AUC0- of eltrombopag was 32% to 36% lower in patients with mild to moderate renal impairment, and 60% lower in patients with severe renal impairment compared with healthy volunteers. 
Nakon jednokratne primjene doze od 50 mg, AUC0- eltrombopaga je bila 32% do 36% niža u bolesnika s blagim do umjerenim oštećenjem bubrega, i 60% niža u bolesnika s teškim oštećenjem bubrega, u odnosu na zdrave dobrovoljce.
When to take it 
Kada uzeti lijek
The efficacy and safety of eltrombopag have not been established in patients with both moderate to severe renal impairment and hepatic impairment. 
Djelotvornost i sigurnost eltrombopaga nije ustanovljena za bolesnike s umjerenim do teškim oštećenjem bubrega i jetre.